Flag of the European Union EU Clinical Trials Register Help

Clinical trials for primary sjogren syndrome

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
    • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.

    The EU Clinical Trials Register currently displays   41018   clinical trials with a EudraCT protocol, of which   6709   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    13 result(s) found for: primary sjogren syndrome. Displaying page 1 of 1.
    EudraCT Number: 2014-003140-12 Sponsor Protocol Number: LEF-HCQinpSS Start Date*: 2015-09-21
    Sponsor Name:UMC Utrecht
    Full Title: Optimizing DMARD-therapy for primary Sjogren's Syndrome - Leflunomide and Hydroxychloroquine combination therapy for patients with primary Sjogren's Syndrome
    Medical condition: Sjogren's Syndrome
    Disease: Version SOC Term Classification Code Term Level
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10040766 Sjogren's disease LLT
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10042846 Syndrome Sjogren's LLT
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10040765 Sjogren's LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003537-16 Sponsor Protocol Number: PR3084 Start Date*: 2008-09-04
    Sponsor Name:Erasmus MC
    Full Title: Estetrol Therapy in Sjogren's Syndrome: An Open Proof of Concept Study
    Medical condition: Primary Sjogren's Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040767 Sjogren's syndrome LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001526-59 Sponsor Protocol Number: CL2-95011-001 Start Date*: 2020-10-20
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: A phase IIa efficacy and safety trial with intravenous S95011 in primary Sjögren’s Syndrome patients. An international, multicentre, randomised, double-blind, placebo-controlled study
    Medical condition: Primary Sjögren’s Syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Ongoing) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003298-22 Sponsor Protocol Number: GLPG3970-CL-207 Start Date*: 2021-01-15
    Sponsor Name:Galapagos NV
    Full Title: A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered GLPG3970 for 12 weeks ...
    Medical condition: Primary Sjogren's Syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) DE (Ongoing) HU (Ongoing) GR (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000417-31 Sponsor Protocol Number: IM101-473 Start Date*: 2014-07-01
    Sponsor Name:University Medical Center Groningen
    Full Title: Randomized, double-blind, placebo-controlled phase III study (ASAP III study) to assess the efficacy and safety of Abatacept treatment in patients with primary Sjögren’s syndrome (ASAP III study = ...
    Medical condition: Primary Sjögren's syndrome (pSS)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004859 10042846 Syndrome Sjogren's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-015558-40 Sponsor Protocol Number: ABACEPT1 Start Date*: 2010-07-28
    Sponsor Name:University Medical Center Groningen
    Full Title: Abatacept treatment in patients with primary Sjögren’s syndrome
    Medical condition: Sjögren’s syndrome (SS) is a chronic, systemic, lymphoproliferative autoimmune disease affecting the exocrine glands. The salivary and lacrimal glands are most commonly affected, resulting in dry m...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10040767 Sjogren's syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-013976-38 Sponsor Protocol Number: COLO400BDE02T Start Date*: Information not available in EudraCT
    Sponsor Name:Charité Berlin, Department of rheumatology [...]
    1. Charité Berlin, Department of rheumatology
    2. Charité Berlin, department of rheumatology
    3. Charité Berlin, department of rheumatology
    Full Title: Phase II Trial of low-dose Sandimmun Optoral ® (Cyclosporine A) for the treatment of primary Sjögren's syndrome (pSS)
    Medical condition: Primary Sjögren's Syndrome
    Disease: Version SOC Term Classification Code Term Level
    12.1 10059142 Sjoegren's syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003292-22 Sponsor Protocol Number: CVAY736A2201 Start Date*: 2017-06-06
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, placebo-controlled multicenter phase 2 dose-ranging study to assess the safety and efficacy of ianalumab doses administered subcutaneously in patients with moderate to s...
    Medical condition: Primary Sjogren’s syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) PT (Completed) GB (GB - no longer in EU/EEA) FR (Completed) NL (Completed) HU (Completed) BE (Completed) AT (Completed) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000511-77 Sponsor Protocol Number: ACT16618 Start Date*: 2020-11-12
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: A randomized, double-blind, placebo-controlled, parallel-group study of the safety, tolerability, pharmacokinetics, and therapeutic efficacy of SAR441344 in adult patients with primary Sjögren’s ...
    Medical condition: Sjögren’s syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002205-22 Sponsor Protocol Number: IM014029 Start Date*: 2020-05-01
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: "A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Efficacy and Safety of Branebrutinib Treatment in Subjects with Active Systemic Lupus Erythematosus or Primary Sjögr...
    Medical condition: SLE Sub-protocol: Systemic Lupus Erythematosus pSS Sub-protocol: Primary Sjögren’s Syndrome RA Sub-protocol: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Ongoing) ES (Ongoing) PL (Ongoing) NL (Ongoing) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001933-11 Sponsor Protocol Number: 73828-041-20 Start Date*: 2021-06-10
    Sponsor Name:University Medical Center Utrecht
    Full Title: Leflunomide and Hydroxychloroquine combination therapy for primary Sjögren’s Syndrome
    Medical condition: Primary Sjogren Syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005757-38 Sponsor Protocol Number: OFTACAMPOS_08_01 Start Date*: 2009-02-10
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: CORD BLOOD SERUM IN THE TREATMENT OF OCULAR SURFACE DISEASES (PILOT STUDY.)
    Medical condition: severe ocular surface disorders and the enhancement of corneal wound healing
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011049 Corneal structural change, deposit and degeneration HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000372-29 Sponsor Protocol Number: JBT101-SSc-002 Start Date*: 2018-03-20
    Sponsor Name:Corbus pharmaceuticals, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
    Medical condition: Systemic Sclerosis (SSc)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10012977 Diffuse systemic sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Completed) ES (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands     Legal notice
    EMA HMA